- Oops!Something went wrong.Please try again later.
DNA sequencing and array-based technologies company Illumina, Inc. (NASDAQ: ILMN) pre-announced second-quarter results Thursday that represent a "big miss" versus expectations, according to Bank of America Merrill Lynch.
Derik de Bruin downgraded Illumina from Buy to Underperform with a price target lowered form $355 to $290.
Illumina said Thursday it expects second-quarter revenue to be roughly flat year-over-year at $835 million, which is short of the $890 million expected, de Bruin said in a Friday note. (See his track record here.)
The miss can be attributed to three areas, the analyst said:
A sizable sequencing systems and consumables purchase that will close later in 2019.
Softness in the direct-to-consumer genomic market.
Low to mid-throughput NGS systems and consumables.
On top of a weak second-quarter pre-announcement, Illumina also lowered its full-year sales growth expectations from 13%-14% to 6%.
The revision is "particularly surprising" after management offered positive commentary over recent months, de Bruin said.
Despite a double downgrade to a bearish stance, the analyst said he remains "emphatically bullish" on the long-term potential and opportunity in the sequencing market.
The ongoing drop in the cost of sequencing has resulted in the company expanding the number of applications, and multiple new markets such as liquid biopsy and population genomics remain in the very early stages, he said.
Investors should view BofA's bearish stance as merely a function of near-term uncertainty and not a reflection of long-term fundamentals, de Bruin said.
Illumina shares were down 15.91% at $305.80 at the time of publication Friday.
The Daily Biotech Pulse: Hookipa Leaps, Illumina Dims On Q2 Warning, Novartis-Amgen Halt Alzheimer's Study
Illumina Shares Slammed On Guidance Warning
Latest Ratings for ILMN
View More Analyst Ratings for ILMN
View the Latest Analyst Ratings
See more from Benzinga
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.